Study of Testosterone vs Placebo in Testicular Cancer Survivors

Inclusion Criteria: * Signed informed consent. * Previous treatment for testicular cancer. * No signs of relapse 1 year after last treatment (orchiectomy, radiotherapy, chemotherapy). * Free testosterone \< the age-adjusted median and \> -2 standard deviations (SD) from the age-adjusted median and LH \> 2 SD from the age-adjusted median. Exclusion Criteria: * Treatment with testosterone within the last 6 months. * Contraindications to testosterone treatment (prostate cancer, prostate specific antigen (PSA)\> 4 ng/mL), malignancy suspect prostate by digital rectal examination, Alanine aminotransferase (ALT)\> 1.5 upper reference level, Erythrocyte Volume Fraction (EVF) \> 50%. * Breast cancer. * Symptomatic obstructive sleep apnoea syndrome * Heart failure \> NYHA II. * Uncontrolled hypertension: (Systolic blood pressure \> 160 mm Hg despite antihypertensive treatment, measured at two separate occasions) * Inability to understand information about the trial * Participation in any other clinical trial * Allergy for the active substance or additives in Tostran or placebo. * Known diabetes mellitus, or diabetes mellitus detected at screening or baseline tests.